Researchers have combined molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood-brain barrier. In the June 1, 2004 issue of the journal *Clinical Cancer Research,* William Pardridge and colleagues have reported that a pegylated immunoliposome (see figure) equipped with two specific antibodies first recognizes the transferrin receptor, a key protein portal of the blood-brain barrier, and then gains entry into brain cancer cells with the second antibody, targeting the human insulin receptor.

Using the antibodies to traverse both the blood-brain barrier and the tumor cell membrane, the liposomes delivered a nonviral plasmid into brain cancer cells. The plasmid encoded a short hairpin RNA (shRNA) designed to interfere with the expression of the epidermal growth factor receptor, EGFR, a potent factor in tumor cell proliferation. When treated with a weekly intravenous dose of the targeted RNA interference (RNAi) therapeutic, mice with brain tumors survived almost twice as long compared to mice that did not receive the treatment.

Model of pegylated immunoliposome (PIL) that is doubly targeted to both the mouse transferrin receptor (mTfR) and the human insulin receptor (HIR) with monoclonal antibodies (mAbs). Encapsulated in the interior of the PIL is the plasmid DNA carrying the gene encoding the short hairpin RNA (shRNA), which is driven by the U6 promoter (pro). Image courtesy W. Pardridge.

"This is the first drug delivery system that demonstrates that by using RNAi technology, you can prolong life threatened by cancer," said Dr. Pardridge. "By solving the delivery problem, powerful molecular tools and therapies such as RNA interference can be moved to clinical trials where they can be tested to see how much benefit the patient gets."

Pardridge explained that the treatment strategy thwarted EGFR function in two ways. EGFR is set into action when it binds a growth factor. Activated EGFR normally induces a flow of calcium across tumor cell membranes. That calcium mobilization was minimized in the brain cancer cells treated with the targeted liposome packet. Furthermore, activated EGFR induces DNA replication and cell proliferation. The workers observed less DNA replication, and hence, cellular proliferation, in the cancer cells that were treated with the immunoliposomes.

*Clinical Cancer Research,* online edition, doi: 10.1158/1078- 0432.ccr-030740

HIV Treatment to Be Tested in Patients {#cesec10}
======================================

Stanford\'s Thomas Merigan is seeking volunteers for a study to test a possible method of empowering an infected person\'s own cells to destroy HIV. The process involves inserting an anti-HIV ribozyme into the patient\'s hematopoietic stem cells. "This is a broad-spectrum treatment that could integrate well with other therapies as the disease progresses, as it will in all patients eventually," said Merigan, who is collaborating with other researchers at UCLA and St. Vincent\'s Hospital in Sydney, Australia, under the sponsorship of Johnson & Johnson Research. "The goal is to genetically engineer the cells and make them resistant to infection."

The strategy relies on the fact that the genetic information of HIV is encoded in RNA rather than DNA. If a ribozyme specific to HIV RNA were present inside the cells that the virus infects, then it could constitute a first- line defense against the virus. A total of seventy patients will be enrolled for this stage of the testing. The participants will be randomly assigned to receive either the ribozyme gene therapy or a dummy gene. Johnson & Johnson Research produces the reagents used for introducing the ribozyme into the cells.

Merigan said that similar studies testing the strategy of using gene therapy in more than 1,200 patients have proven the technique to be safe. The safety studies for the current trial looked at a total of fourteen patients and found no safety concerns. Due to a scare a few years ago when two babies undergoing gene therapy developed leukemia, Merigan noted that the HIV trial was delayed for two years while the trial\'s safety design was examined by the NIH, the FDA and local review boards. He said the verdict was that the immune system of adults with HIV differs greatly from that of babies, whose immune systems are not fully formed, and that they should not face the same risk.

FDA Issues New Rules on Donor Tissue Eligibility {#cesec20}
================================================

The FDA has published a final rule establishing eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the trans-mission of communicable disease when these products are transplanted. This final rule requires that, before the use of most HCT/Ps, the cell or tissue donor must be found eligible, based on the results of screening for risk factors and testing for relevant communicable diseases. The new rule pertains to donors of traditional tissues such as musculoskeletal, skin and eye tissues that have been required to be screened and tested for HIV, Hepatitis B virus (HBV) and Hepatitis C virus (HCV) since 1993. Under this new rule, reproductive tissue (semen, ova, and embryos), hematopoietic stem cells derived from cord blood and peripheral blood sources (circulating blood sources as opposed to bone marrow), cellular therapies and other innovative products are also regulated.

In addition to including a broader range of tissues and cells, the new rule extends the scope of protection against additional communicable diseases, adding requirements to screen for human transmissible spongiform encephalopathies, including Creutzfeldt-Jakob disease (CJD), and to screen for syphilis. Screening for human T-lymphotropic virus (HTLV) would be required for viable cells and tissues rich in leukocytes such as semen and hematopoietic stem cells. For reproductive tissues, *Chlamydia trachomatis* and *Neisseria gonorrhoeae* also pose potential risks and are included.

The new rule also provides a framework for identifying emerging diseases so as to give the FDA the flexibility to rapidly address new disease threats. Examples of such diseases include West Nile virus, Severe Acute Respiratory Syndrome (SARS) and sepsis. Exceptions from the requirements include autologous HCT/Ps and reproductive cells or tissues from a sexually intimate partner. The new framework does not include whole organs or minimally-manipulated bone marrow, which are regulated by HRSA, another agency of the Department of Health and Human Services. It also does not cover blood products for transfusion or products derived from animals, which FDA regulates under the biologics license requirements and other applicable regulations. The rule is available on FDA\'s website at [www.fda.gov/OHRMS/DOCKETS/98fr/97N-484S-nfr0001.pdf](http://www.fda.gov/OHRMS/DOCKETS/98fr/97N-484S-nfr0001.pdf){#interrefs10} and the guidance is available at [www.fda.gov/cber/gdlns/tissdonor.pdf](http://www.fda.gov/cber/gdlns/tissdonor.pdf){#interrefs20}.

Gene Transfer Reduces Drinkng in Alcoholic Rats {#cesec30}
===============================================

Scientists have used viral gene transfer to cut drinking in rats with a genetic predisposition for heavy alcohol consumption. The findings, along with additional results on the effects of long-term ethanol consumption on certain aspects of brain chemistry, are published in the May 2004 issue of *Alcoholism Clinical and Experimental Research.* "Though we are still early in the process, these results improve our understanding of the mechanism or mechanisms of alcohol addiction and strengthen our hope that this treatment approach might one day help people addicted to alcohol," said Panayotis (Peter) Thanos, who lead the study.

Rats genetically predisposed to consuming alcohol are better models for human alcoholism than the rats used previously, which the scientists had trained to prefer alcohol. The genetic alcohol-preferring rats drink, on average, more than five grams of ethanol per kilogram of body weight per day when given a free choice between alcohol and water, compared to only one gram of ethanol for the normal rats.

In this study, both groups were treated with gene transfer to increase the level of a brain receptor for dopamine, a chemical important for transmitting feelings of pleasure and reward and known to play a role in addiction. After treatment, the alcohol-preferring rats exhibited a 37 percent reduction in their preference for alcohol and cut their total alcohol consumption in half. Normal rats also reduced their drinking preference and intake after gene treatment, but not in nearly as dramatic a fashion.

The gene encoded the dopamine D2 receptor (D2R), shown in various studies to be relevant to alcohol and drug abuse. The alcohol-preferring rats have about 25 percent lower levels of dopamine D2 receptors when compared to normal rats, which may, in part, explain their tendency toward heavy drinking. A virus encoding D2R was injected into the rats' nucleus accumbens, the brain\'s pleasure center. Micro-positron emission tomography (microPET) was then used to assess the effects of chronic alcohol consumption on D2 receptor levels in alcohol-preferring and normal rats. They measured D2 levels seven weeks after the gene therapy treatment (well after the effects of gene therapy had worn off). D2 receptor levels in alcohol-preferring rats were significantly lower (about 16 percent) compared to that in normal rats. These levels were similar to previous data in naive preferring and non-preferring rats.

In future studies, the D2 connection to alcoholism will be examined in transgenic mice that are depleted of D2. In addition, the scientists plan to develop a second generation D2 vector approach that will provide a longer period of treatment. "These findings further support our hypothesis that high levels of D2 are causally associated with a reduction in alcohol drinking and may serve as a protective factor against alcoholism," Thanos said.

*Alcoholism: Clinical and Experimental Research, (2004), **28:** 720-8, doi not provided by publisher.*
